

## Glenmark receives tentative approval for new generic

18 March 2016 | News | By BioSpectrum Bureau

### Glenmark receives tentative approval for new generic



Glenmark Pharmaceuticals USA (Glenmark) has been granted tentative approval by the United States Food and Drug Administration (US FDA) its Lacosamide Oral Solution, 10 mg/mL, the generic version of Vimpat Oral Solution, 10 mg/mL of UCB, Inc.

Glenmark will market this product upon receiving final approval of its Lacosamide Oral Solution, 10 mg/mL ANDA. The patent listed in the Orange Book for Vimpat Oral Solution, 10 mg/mL is scheduled to expire on March 17, 2022.

According to IMS Health sales data for the 12 month period ending January 2016, the Vimpat market achieved annual sales of approximately \$55.4 million.